109 related articles for article (PubMed ID: 25394571)
1. Potential long term vaccine benefits poorly translate in cost effectiveness modelling.
Black S
BMJ; 2014 Nov; 349():g6764. PubMed ID: 25394571
[No Abstract] [Full Text] [Related]
2. Cost effectiveness has its place, but so does common sense.
Rappuoli R; Wassil J; Bonefeld L; Porter J
BMJ; 2014 Nov; 349():g6759. PubMed ID: 25394622
[No Abstract] [Full Text] [Related]
3. Winter is coming: vaccine negotiations should be concluded swiftly.
Glennie L; Wright C; Head C
BMJ; 2014 Nov; 349():g6748. PubMed ID: 25394501
[No Abstract] [Full Text] [Related]
4. Authors' reply to Rappuoli and colleagues, Black, and Glennie and colleagues.
Christensen H; Trotter CL; Hickman M; Edmunds WJ
BMJ; 2014 Nov; 349():g6758. PubMed ID: 25394639
[No Abstract] [Full Text] [Related]
5. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.
Christensen H; Trotter CL; Hickman M; Edmunds WJ
BMJ; 2014 Oct; 349():g5725. PubMed ID: 25301037
[TBL] [Abstract][Full Text] [Related]
6. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.
Miller MA; Shahab CK
Pharmacoeconomics; 2005; 23(4):333-43. PubMed ID: 15853434
[TBL] [Abstract][Full Text] [Related]
7. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
8. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad.
Lydon P; Zipursky S; Tevi-Benissan C; Djingarey MH; Gbedonou P; Youssouf BO; Zaffran M
Bull World Health Organ; 2014 Feb; 92(2):86-92. PubMed ID: 24623901
[TBL] [Abstract][Full Text] [Related]
9. Is there a need for a public vaccine production capacity at European level?
Levy-Bruhl D
Euro Surveill; 2006 Jul; 11(7):148-9. PubMed ID: 16966801
[No Abstract] [Full Text] [Related]
10. Methodological concerns with economic evaluations of meningococcal vaccines.
Kauf TL
Pharmacoeconomics; 2010; 28(6):449-61. PubMed ID: 20465314
[TBL] [Abstract][Full Text] [Related]
11. Neisseria meningitidis serogroup A vaccines: an overview.
Vergnano S; Heath P
Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
[TBL] [Abstract][Full Text] [Related]
12. Perspective: Elimination round.
Artenstein AW; Poland GA
Nature; 2014 Mar; 507(7490):S16. PubMed ID: 24611173
[No Abstract] [Full Text] [Related]
13. Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks?
Roberts L
Science; 2010 Dec; 330(6010):1466-7. PubMed ID: 21148362
[No Abstract] [Full Text] [Related]
14. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
[TBL] [Abstract][Full Text] [Related]
15. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].
Gendrel D
Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370
[TBL] [Abstract][Full Text] [Related]
16. The real cost of an affordable vaccine for meningococcus A.
Rappuoli R
Lancet; 2003 Jul; 362(9379):250-1; author reply 251. PubMed ID: 12885501
[No Abstract] [Full Text] [Related]
17. Meningococcal vaccination: cui bono?
Szucs TD
Pharmacoeconomics; 2005; 23(4):315-6. PubMed ID: 15853431
[No Abstract] [Full Text] [Related]
18. [Africa: towards the eradication of meningitis A?].
Nau JY
Rev Med Suisse; 2011 Jun; 7(300):1378-9. PubMed ID: 21815540
[No Abstract] [Full Text] [Related]
19. Meningitis B vaccine to be introduced in UK after U turn on its cost effectiveness.
Wise J
BMJ; 2014 Mar; 348():g2327. PubMed ID: 24665138
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
De Wals P; Nguyen VH; Erickson LJ; Guay M; Drapeau J; St-Laurent J
Vaccine; 2004 Mar; 22(9-10):1233-40. PubMed ID: 15003652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
